We serve Chemical Name:bis(2,5-dioxopyrrolidin-1-yl) decanedioate CAS:23024-29-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

bis(2,5-dioxopyrrolidin-1-yl) decanedioate

Chemical Name:bis(2,5-dioxopyrrolidin-1-yl) decanedioate
CAS.NO:23024-29-5
Synonyms:Decanedioic Acid Di(N-succinimidyl) Ester;BICL114;disuccinimidyl sebacoate;Di(N-succinimidyl) Decanedioate;Disuccinimidyl Sebacate;DSSeb;Sebacic acid bis(N-succinimidyl) ester;Sebacic Acid Di(N-succinimidyl) Ester;Di(N-succinimidyl) sebacate;Di(N-succinimidyl) Sebacate
Molecular Formula:C18H24N2O8
Molecular Weight:396.39200
HS Code:2925190090

Physical and Chemical Properties:
Melting point:162-167ºC
Boiling point:532.8ºC at 760mmHg
Density:1.34g/cm3
Index of Refraction:1.547
PSA:127.36000
Exact Mass:396.15300
LogP:1.19740

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:


Contact us for information like Decanedioic Acid Di(N-succinimidyl) Ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Di(N-succinimidyl) Sebacate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Disuccinimidyl Sebacate Use and application,Disuccinimidyl Sebacate technical grade,usp/ep/jp grade.


Related News: In its message to the public, the FDA said that a person should consider being retested if they used Innova’s diagnostic within the past two weeks. bis(2,5-dioxopyrrolidin-1-yl) decanedioate manufacturer To persuade doctors to stop treatment for a traditionally continuous therapy, AbbVie and J&J likely also need to show that doing so won’t hurt patients’ chance at successful retreatment if their cancer does rebound early. bis(2,5-dioxopyrrolidin-1-yl) decanedioate supplier ��We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,�� said Ed Damiano, President and CEO of Beta Bionics. ��We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.�� bis(2,5-dioxopyrrolidin-1-yl) decanedioate vendor One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. bis(2,5-dioxopyrrolidin-1-yl) decanedioate factory One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively.